Benign metastasizing leiomyoma

Summary

Benign metastasizing leiomyoma (MONDO:0022560) is a disease. A subtype of leiomyoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign metastasizing leiomyoma
Mondo ID	MONDO:0022560
UMLS	C1511090
MedGen	307261
Is cancer (heuristic)	no

Disease family

This is a subtype of leiomyoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma › benign metastasizing leiomyoma

Related subtypes (29): laryngeal leiomyoma, gastric leiomyoma, ureter leiomyoma, vaginal leiomyoma, bladder leiomyoma, breast leiomyoma, small intestine leiomyoma, urethra leiomyoma, trachea leiomyoma, prostate leiomyoma, mediastinum leiomyoma, fallopian tube leiomyoma, central nervous system leiomyoma, bizarre leiomyoma, deep leiomyoma, leiomyoma cutis, lung leiomyoma, pericardium leiomyoma, leiomyomatosis, cellular leiomyoma, gallbladder leiomyoma, vulvar leiomyoma, colorectal leiomyoma, liver leiomyoma, esophagus leiomyoma, renal leiomyoma, myofibroma, uterine corpus leiomyoma, leiomyoma of ciliary body

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.